Severe acute respiratory syndrome corona virus 2(SARS-CoV-2), the causative agent of corona virus disease-2019(COVID- 19) which has led to a global pandemic. The true extent of the burden of COVID-19 may be underestimated, and there is need to know the current prevalence of SARS-CoV-2 antibody in population. The present study was a cross-sectional study to assess prevalence of SARS-CoV- 2 IgG antibody among 586 healthy voluntary blood donors who donated whole blood between mid-December 2020 to January 2021. A chemiluminescence assay was used to detect the presence of SARS-CoV-2 IgG antibody in serum samples in addition to recommended transfusion transmitted infections tests and Signal to Cut Off (S/C) > 1 was considered as reactive for antibody as per manufacturer’s instructions. In the present study, 586 healthy voluntary blood donors were enrolled and were screened for SARS- CoV-2 IgG antibody. Out of 586 donors, 52 donors had indeterminate values of SARS-CoV-2 IgG antibody. A total of 534 healthy voluntary blood donors’ samples were included in the present study for analysis. Out of total 534 healthy blood donors, 42.88% (229) were found to be seropositive while 57.11% (305) were found to be seronegative. A 43% positivity of SARS-CoV-2 IgG antibody among healthy blood donors was detected which is an indication of presence of infection at community level and majority of the population already has been exposed to SARS-CoV-2 infection. However, there was no statistically significant association of type of blood group and age with seropositivity.
Introduction: Non-Small Cell Lung Cancers (NSCLC) is classified into squamous cell carcinoma and adenocarcinoma. Adenocarcinoma is commonly seen in non smoking females. Epidermal Growth Factor Receptor (EGFR) is a tyrosine kinase receptor which gets mutated in lung cancer. Tyrosine Kinase Inhibitors (TKI) like gefitinib are known to a have a good response in lung adenocarcinoma. Aim: The aim of this study was to detect EGFR mutations in NSCLC and associate the mutation status with clinicopathological parameters. Materials and Methods: The present cross-sectional study was conducted in the Department of Oncopathology and Transplant Immunology Molecular lab at Mahatma Gandhi Hospital, Jaipur, Rajasthan, India, from June 2023 to May 2024. All histopathological diagnosed cases of NSCLC were included in the study. Immunohistochemistry was further applied. EGFR mutation status (19Del, T790M, S768I, C797S, Ex20ins, G719X, L858R, L861Q) was checked using Real Time Polymerase Chain Reaction (PCR). An attempt was made to find out the association between the mutation status and various clinicopathological parameters. Statistical analysis was done using Statistical Package for Social Sciences (SPSS) statistics software windows version 22.0 released 2013. Results: A total of 37 cases were included in the study of which 21 were males and 16 were females. There was near equal distribution when a comparison of smoking status was done. The most common clinical symptom was cough and the most common histological type was acinar adenocarcinoma. Thirteen out of 37 cases showed EGFR mutations. Exon 19 deletion was the most common mutation. EGFR mutation status showed statistical significance with non smokers and acinar adenocarcinoma. Conclusion: Adenocarcinomas are more commonly seen in non smoking females. Exon 19 deletion is the most common type of EGFR mutation seen in lung adenocarcinomas. Mutations in EGFR are associated with good response to TKI.
31 July 2023 in Journal of South Asian Federation of Obstetrics and Gynaecology